WINNIPEG, Manitoba - (June 2, 2003) - Medicure
Inc. (TSE:MPH), a cardiovascular drug discovery and development
company, is pleased to announce that it has been accepted to participate
in the Business Forum of BIO 2003, the world's largest gathering
of biotechnology companies and their leaders. The Business Forum
at BIO 2003 will be a medium where investors and pharmaceutical
executives will have the opportunity to hear from biotechnology
companies located around the world. The Annual Convention, takes
place June 22 - 25, 2003, in Washington, D.C.
"We look forward to having this opportunity to present the
Medicure story to an audience on a world stage such as BIO 2003,"
said Albert D. Friesen, Ph.D., Medicure Chairman, President and
CEO. "We believe we have a very exciting and positive story
to tell and our participation in this conference reflects a growing
recognition of Medicure, its strong pipeline of products, our proprietary
technology and our superlative scientific team."
Medicure will make its presentation at 3 p.m. on Tuesday, June
24, 2003.
A key component of the Business Forum, in the addition to the corporate
presentation, is the opportunity for presenting companies to schedule
one-on-one meetings with representatives of pharmaceutical, biotechnology
and other healthcare-focused companies, along with members of the
financial community and the media.
Celebrating its 10th anniversary this year, BIO has grown tenfold
since its inception and by more than 45% in the last two years alone.
More than 17,000 delegates, including biotech executives, politicians,
scientists, industry officials and potential investors are expected
at the four-day conference. In addition, some 500-plus journalists
from all parts of the world are expected to be at the Conference,
as well. BIO 2003 is planning 26 tracks of programming, including
sessions on bioethics, business development, science, regulatory
affairs, and others.
About Medicure
Inc.
Medicure Inc. is a cardiovascular
drug discovery and development Company focused on developing effective
therapeutics for unmet needs in the field of cardiovascular medicine
including the prevention and treatment of ischemia, ischemic reperfusion
injury, and stroke.
This press release
contains forward-looking statements that involve risks, which may
cause actual results to differ materially from the statements made,
and accordingly may be deemed to be forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
made as of the date hereof, and the Company disclaims any intention
and has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
For more information, please contact:
Derek Reimer
Chief Financial Officer
Don Bain
Director of Investor & Public Relations
Medicure Inc.
888-435-2220
204-488-9823 fax
info@medicure.com
Back to 2003 News Archives
